Atazanvir/ritonavir + efavirenz — Competitive Intelligence Brief

Atazanvir/ritonavir + efavirenz (Atazanvir/ritonavir + efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (protease inhibitor + NNRTI). Area: Infectious Disease.

phase 3 Antiretroviral combination (protease inhibitor + NNRTI) HIV protease, HIV reverse transcriptase Infectious Disease Small molecule

Target snapshot

Atazanvir/ritonavir + efavirenz (Atazanvir/ritonavir + efavirenz) — Bristol-Myers Squibb. This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atazanvir/ritonavir + efavirenz TARGET	Atazanvir/ritonavir + efavirenz	Bristol-Myers Squibb	phase 3	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase
Darunavir / Ritonavir + Tenofovir / Emtricitabine	Darunavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Atazanavir, ritonavir, lamivudine	Atazanavir, ritonavir, lamivudine	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (protease inhibitor + NRTI)	HIV protease, HIV reverse transcriptase
Atazanavir/ Stavidine / Lamivudine	Atazanavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Atazanavir + Ritonavir + 2 NRTIs	Atazanavir + Ritonavir + 2 NRTIs	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, cytochrome P450 (CYP3A4)
atazanavir/tenofovir/emtricitabine	atazanavir/tenofovir/emtricitabine	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Lopinavir/ritonavir + zidovudine + lamivudine	Lopinavir/ritonavir + zidovudine + lamivudine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (protease inhibitor + NNRTI) class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Imperial College London · 1 drug in this class
3. St Stephens Aids Trust · 1 drug in this class